Authors: SPARREBOOM A PLANTING AST JEWELL RC PAUL EM WISSEL PS DEBRUIJN P NOOTER K STOTER G VERWEIJ J

Citation: A. Sparreboom et al., CLINICAL PHARMACOKINETICS OF DOXORUBICIN IN COMBINATION WITH GF120918, A POTENT INHIBITOR OF MDR1 P-GLYCOPROTEIN, Annals of oncology, 9, 1998, pp. 550-550

Authors: WITHERSPOON SM EMERSON DL KERR BM LLOYD TL DALTON WS WISSEL PS

Citation: Sm. Witherspoon et al., FLOW CYTOMETRIC ASSAY OF MODULATION OF P-GLYCOPROTEIN FUNCTION IN WHOLE-BLOOD BY THE MULTIDRUG-RESISTANCE INHIBITOR GG918, Clinical cancer research, 2(1), 1996, pp. 7-12

Authors: KERR BM DAVIS IM WITHERSPOON SM EMERSON DL DALTON WS MANN MB WISSEL PS

Citation: Bm. Kerr et al., PHARMACOKINETICS (PK) AND DYNAMICS (PD) OF THE MULTIDRUG-RESISTANCE (MDR) INHIBITOR GG918 IN HEALTHY-VOLUNTEERS (HVTS), Clinical pharmacology and therapeutics, 59(2), 1996, pp. 40-40

Authors: KUNKA RL ECKARDT JR VERWEIJ J DEPEE SP LITTLEFIELD D SELINGER KA BERANEK P COLLIS P WISSEL PS

Citation: Rl. Kunka et al., USE OF PHARMACOKINETICS AS A TOOL IN PREDICTING TOXICITY OF GG211, A NEW TOPOISOMERASE-I INHIBITOR, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 175-175

Authors: WITHERSPOON SM EMERSON DL KERR BM DALTON WS WISSEL PS

Citation: Sm. Witherspoon et al., FLOW CYTOMETRIC ASSAY OF MODULATION OF P-GLYCOPROTEIN FUNCTION IN CD56+ LEUKOCYTES BY THE MDR INHIBITOR GF120918, Blood, 84(10), 1994, pp. 10000615-10000615